Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 196

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 196
---
          — 
 10,578,865 
 10,578,865 
  7,912,454 
    504,749 
  8,417,203 | ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) |
|:-----------------------------------------------------------------------------------------------------|:----|:-------------|-----------:|:--|:----|:--------------|-----------:|:--|
| Interest                                                                                             |     | $            |    164,807 |   |     | $             |     39,201 |   |
| Income taxes                                                                                         |     | $            |          — |   |     | $             |          — |   |
| Supplemental non-cash financing activities:                                                          |     |              |            |   |     |               |            |   |
| Common stock issued for conversion of accrued interest, as restated                                  |     | $            |          — |   |     | $             |     16,340 |   |
| Common stock issued upon conversion of convertible debt and                                          
 exercise of related warrants, as restated                                                            |     | $            |  2,697,849 |   |     | $             |  1,199,916 |   |
| Common stock issued for exercise of warrants with settlement of notes payable, as restated           |     | $            |          — |   |     | $             |  2,153,124 |   |
| Common shares issued for dividends on and conversion of                                              
 Series A convertible preferred stock, as restated                                                    |     | $            |          — |   |     | $             |    402,064 |   |
| Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively, as restated |     | $            |     90,816 |   |     | $             |     14,662 |   |
| Reclassification of fair value of warrant liabilities to equity, as restated                         |     | $            |          — |   |     | $             |    881,553 |   |
| Initial recognition of right of use asset and liability                                              |     | $            |    365,556 |   |     | $             |          — |   |

<div align='center'>The accompanying notes are an integral part of these consolidated financial statements.</div>

| F-25 |

<div align='center'>Sh